Resources
Resource types
- Poster
We evaluated 6-base sequencing with duet evoC, which simultaneously profiles 5mC, 5hmC, genetic variants and fragmentomics features from a single cfDNA sample.
- Poster
The ssDNA duet workflow achieves ultra‑low limits of detection by combining high material recovery with outstanding sensitivity and specificity across genomic and epigenetic features.
- Poster
Serial plasma dual 5mC/5hmC profiling moved liquid biopsy beyond mutation detection toward transcriptome-like tumor-state and resistance monitoring in mCRPC
- Poster
We investigated the impact of a duet single stranded ligation workflow on methylation LoD (further details on duet single stranded ligation workflow are provided in poster #121) across duet +modC (which provides 5-base data) and duet evoC (which provides 6-base data, distinguishing between 5mC and 5mC).
- Poster
We demonstrate the value of integrating genetic and epigenetic information from a single cfDNA assay using the duet evoC technology, which enables simultaneous extraction of complete genetics and complete epigenetics from the same sample.
- Poster
Here, we assess the contribution of combined fragmentomic and epigenetic features to ctDNA detection in cfDNA from healthy individuals and colorectal cancer (CRC) patients.
- Poster
This study demonstrates the value of moving beyond legacy epigenetic sequencing technologies that provide a modC readout.
- Poster
This poster demonstrates compatibility of duet evoC with formalin-damaged DNA including clinical FFPE samples.
- Poster
Patterns of 5hmC and 5hmC provide insight into tissue-specific gene expression with the ability to better distinguish high and low expressed genes than 5mC or 5modC data.
- Poster
Using modality XPLR, we reveal variation in 5mC and 5hmC levels across tissues, with a pronounced increase in 5hmC in cerebellum and concomitant decrease in 5mC.
- Poster
Patterns of 5hmC and 5hmC provide a view on tissue-specific gene expression.
- Poster
The combination of PARPi (Talazoparib – TAL) and DNMTi (Decitabine – DAC) functions synergistically to inhibit PCa cell lines and patient-derived PTOs.